만성 대장염 관련 대장암의 뮤린 충수 절제술 모델은 Caecal 패치의 정확한 국소화에 의해

Executive Industry Relevance

The murine appendectomy model enables mechanistic investigation of the appendix in gut immune regulation and microbiota homeostasis, providing a disease-relevant system to study colorectal cancer pathogenesis. By linking appendectomy to colitis-associated tumor development, the model supports target validation and de-risking of hypotheses linking lymphoid tissue to tumorigenesis. This preclinical model offers predictive value for evaluating therapeutic interventions targeting gut-associated immune pathways in oncology pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates the therapeutic hypothesis that the appendix modulates gut-associated lymphoid tissue and immune responses relevant to colorectal cancer development.
• Operational Value: Provides a reproducible surgical model to assess changes in IgA+ plasma cells and secretory IgA as biomarkers of intestinal immune function.
• Predictive Value: Enables evaluation of how appendix removal influences tumor initiation and progression in a colitis-associated cancer context.

Screening & Assay Development

• Scientific Value: Generates a standardized disease model with quantifiable histological endpoints including mucosal ulceration, neutrophil infiltration, and adenocarcinoma staging.
• Operational Value: Supports assay readiness through consistent induction of colitis-associated tumors using DSS and AOM, enabling compound screening in a controlled inflammatory microenvironment.
• Translational Value: Facilitates biomarker qualification efforts by correlating immune alterations (e.g., IgA reduction) with histopathological disease severity.

Translational & Preclinical Research

• Scientific Value: Models the continuum from immune dysregulation to tumorigenesis, allowing study of inflammatory drivers in colorectal cancer.
• Operational Value: Demonstrates high survival (~80%) and minimal weight loss, supporting longitudinal study designs and repeated dosing regimens.
• Risk Mitigation: Enables mechanistic de-risking by isolating the variable of appendectomy in a defined genetic background (C57BL/6) to assess its impact on disease penetrance.

Pipeline & Workflow Integration

The model fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing, particularly for immunomodulatory or microbiome-modulating agents.

• Discovery Biology: Tests hypotheses regarding the appendix’s role in gut immune regulation and microbial homeostasis using measurable immune and histopathological outputs.
• Screening: Provides a standardized, inducible colitis-associated cancer model suitable for evaluating therapeutic candidates in a pathophysiologically relevant setting.
• Analytics: Delivers quantitative and qualitative readouts including flow cytometry for IgA+ cells, ELISA for secretory IgA, and histology for tumor grade and inflammation.
• Translational Research: Bridges discovery to preclinical validation by modeling a human-relevant disease sequence (inflammation to cancer) in a genetically tractable system.
• Enterprise Reuse: Establishes a reusable platform for studying gastrointestinal immune-oncology interactions across multiple therapeutic areas.

Operational & Enterprise Impact

• Scientific Value: Enhances target confidence by linking a defined anatomical manipulation (caecal patch removal) to measurable immune and neoplastic outcomes.
• Operational Value: Delivers a standardized, scalable surgical procedure with clear postoperative monitoring criteria to ensure model reproducibility across sites.
• Strategic Value: Informs go/no-go decisions by providing mechanistic insights into immune-mediated tumor promotion or suppression.
• Portfolio Impact: Supports risk-adjusted prioritization of immunomodulatory candidates by validating disease-relevant biological activity in a preclinical setting.

Implementation Considerations

• Requires expertise in murine surgical techniques, including vascular ligation and intestinal handling to prevent postoperative complications.
• Dependent on sterile surgical instrumentation, sutures (8-0 and 4-0), disinfectants (entoiodine, alcohol), and postoperative analgesics (buprenorphine).
• Necessitates standardized postoperative care protocols, including heat support and pain monitoring for three days to ensure model validity.
• Requires precise DSS concentration (2%) and AOM dosing (0.01 mL/g) to achieve consistent colitis-associated tumorigenesis without excessive mortality.
• Model applicability may vary across mouse strains due to differences in DSS sensitivity, necessitating strain-specific optimization.

Biopharma FAQs